Array BioPharma (Nasdaq: ARRY) today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study ...
Good day ladies and gentlemen and welcome to the Array BioPharma Incorporated Q1 Fiscal 2016 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct ...
ARRAY BIOPHARMA ($ARRY) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.13 per share, beating estimates of $0.09 by $0.04 ...
Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015. Ron Squarer, Chief Executive Officer of Array, noted, ...
Welcome to the Array BioPharma Conference Call. My name is Don and I will be the operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a ...
Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...
Success in trials of new drugs for metastatic melanoma propelled the stock of Array Biopharma (NASDAQ: ARRY) 115% in 2016. However, after a string of successes, Array hit a setback earlier this week: ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The Securities and Exchange Commission has settled ...
NEW YORK (Reuters) - Array BioPharma Inc on Thursday sued AstraZeneca AB , accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The Dow and Nasdaq finished January trading with a mixed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results